Cargando…

Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin

We are reporting a timely case of atypical euglycemic diabetic ketoacidosis in a type 1 diabetic patient treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitor canagliflozin. The clinical history, physical examination findings and laboratory values are described. Other causes of acidosis suc...

Descripción completa

Detalles Bibliográficos
Autores principales: Bader, Nimrah, Mirza, Lubna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Professional Medical Publications 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928443/
https://www.ncbi.nlm.nih.gov/pubmed/27375734
http://dx.doi.org/10.12669/pjms.323.9201
_version_ 1782440442370981888
author Bader, Nimrah
Mirza, Lubna
author_facet Bader, Nimrah
Mirza, Lubna
author_sort Bader, Nimrah
collection PubMed
description We are reporting a timely case of atypical euglycemic diabetic ketoacidosis in a type 1 diabetic patient treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitor canagliflozin. The clinical history, physical examination findings and laboratory values are described. Other causes of acidosis such as salicylate toxicity or alcohol intoxication were excluded. Ketoacidosis resolved after increasing dextrose and insulin doses supporting the hypothesis that SGLT-2 inhibitors may lead to hypoinsulinemia. Euglycemic ketoacidosis did not recur in our patient after discontinuing canagliflozin. We recommend reserving SGLT2 inhibitor therapy to type 2 diabetics, discontinuing medication and treating patients presenting with ketoacidosis due to SGLT-2 inhibitors with higher concentrations of dextrose with appropriate doses of insulin to help resolve acidosis.
format Online
Article
Text
id pubmed-4928443
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Professional Medical Publications
record_format MEDLINE/PubMed
spelling pubmed-49284432016-07-01 Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin Bader, Nimrah Mirza, Lubna Pak J Med Sci Case Report We are reporting a timely case of atypical euglycemic diabetic ketoacidosis in a type 1 diabetic patient treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitor canagliflozin. The clinical history, physical examination findings and laboratory values are described. Other causes of acidosis such as salicylate toxicity or alcohol intoxication were excluded. Ketoacidosis resolved after increasing dextrose and insulin doses supporting the hypothesis that SGLT-2 inhibitors may lead to hypoinsulinemia. Euglycemic ketoacidosis did not recur in our patient after discontinuing canagliflozin. We recommend reserving SGLT2 inhibitor therapy to type 2 diabetics, discontinuing medication and treating patients presenting with ketoacidosis due to SGLT-2 inhibitors with higher concentrations of dextrose with appropriate doses of insulin to help resolve acidosis. Professional Medical Publications 2016 /pmc/articles/PMC4928443/ /pubmed/27375734 http://dx.doi.org/10.12669/pjms.323.9201 Text en Copyright: © Pakistan Journal of Medical Sciences http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Bader, Nimrah
Mirza, Lubna
Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin
title Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin
title_full Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin
title_fullStr Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin
title_full_unstemmed Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin
title_short Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin
title_sort euglycemic diabetic ketoacidosis in a 27 year-old female patient with type-1-diabetes treated with sodium-glucose cotransporter-2 (sglt2) inhibitor canagliflozin
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928443/
https://www.ncbi.nlm.nih.gov/pubmed/27375734
http://dx.doi.org/10.12669/pjms.323.9201
work_keys_str_mv AT badernimrah euglycemicdiabeticketoacidosisina27yearoldfemalepatientwithtype1diabetestreatedwithsodiumglucosecotransporter2sglt2inhibitorcanagliflozin
AT mirzalubna euglycemicdiabeticketoacidosisina27yearoldfemalepatientwithtype1diabetestreatedwithsodiumglucosecotransporter2sglt2inhibitorcanagliflozin